Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Abnormalities

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,917 result(s) found for: Abnormalities. Displaying page 39 of 146.
    «« First « Previous 35  36  37  38  39  40  41  42  43  Next» Last»»
    EudraCT Number: 2021-004467-26 Sponsor Protocol Number: DIUR015 Start Date*: 2022-02-08
    Sponsor Name:Neurocrine UK Limited
    Full Title: A Phase 3 Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia
    Medical condition: Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001237-41 Sponsor Protocol Number: NLCG-2013.1 Start Date*: 2013-06-05
    Sponsor Name:Norwegian University of Science and Technology
    Full Title: A Randomized Phase III Study Comparing Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer
    Medical condition: Advanced non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000138-33 Sponsor Protocol Number: R4461-PLD-20100 Start Date*: 2021-12-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy
    Medical condition: Familial Partial Lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10053857 Partial lipodystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004113-13 Sponsor Protocol Number: CLDE225XBE01T Start Date*: 2012-11-05
    Sponsor Name:GZA vzw, GZA Ziekenhuizen, Sint-Augustinus
    Full Title: A Phase II, Open-Label, Safety, Efficacy and Pharmacodynamic Study of oral sonidegib in patients with Basal Cell Carcinoma (BCC) and prior exposure to Hedgehog Pathway inhibitors
    Medical condition: Basal Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002030-36 Sponsor Protocol Number: CA2097DX Start Date*: 2019-11-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer
    Medical condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DE (Completed) FR (Completed) BE (Completed) CZ (Completed) IT (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000306-29 Sponsor Protocol Number: 20103 Start Date*: 2021-10-04
    Sponsor Name:Bayer AG
    Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NY...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) AT (Completed) HU (Completed) BG (Completed) PT (Completed) NL (Completed) SK (Completed) GR (Completed) CZ (Completed) LT (Completed) FI (Completed) LV (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-006042-33 Sponsor Protocol Number: KAMON2 Start Date*: 2007-02-01
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or...
    Medical condition: patients affected by HIV and chronic HCV or compensated cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000807 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005996-17 Sponsor Protocol Number: KAMON1 Start Date*: 2007-02-02
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepat...
    Medical condition: PATIENTS AFFECTED BY HIV/HCV NAIVES FROM THERAPIES
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000807 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002762-13 Sponsor Protocol Number: AAML1831 Start Date*: 2025-10-06
    Sponsor Name:Children's Oncology Group
    Full Title: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for ...
    Medical condition: Childhood de novo acute myeloid leukemia (AML)
    Disease:
    Population Age: Newborns, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-005032-30 Sponsor Protocol Number: FLT201-01 Start Date*: 2023-03-13
    Sponsor Name:Freeline Therapeutics Limited
    Full Title: A Phase 1/2, open-label, safety, tolerability and efficacy study of FLT201 in adult patients with Gaucher disease Type 1 (Galileo-1)
    Medical condition: Type 1 Gaucher Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    20.0 10010331 - Congenital, familial and genetic disorders 10075697 Gaucher's disease type I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-003836-22 Sponsor Protocol Number: 114-NH-301 Start Date*: 2007-03-15
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory,...
    Medical condition: Relapsed or Refractory, Follicular Non-Hodgkin’s Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029627 Non-Hodgkin's lymphoma unspecified histology intermediate grade refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) LT (Prematurely Ended) GB (Completed) SE (Prematurely Ended) IT (Prematurely Ended) ES (Completed) LV (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005157-75 Sponsor Protocol Number: EMN12/HO129 Start Date*: 2015-08-06
    Sponsor Name:HOVON Foundation
    Full Title: Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients
    Medical condition: Primary plasma cell leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035223 Plasma cell leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Prematurely Ended) NO (Completed) DK (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012179-82 Sponsor Protocol Number: B0401005 Start Date*: 2010-01-05
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-001641-79 Sponsor Protocol Number: 64041575RSV2001(ALS-8176-505) Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administer...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005346-37 Sponsor Protocol Number: F1D-MC-HGMR Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental ...
    Medical condition: children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061345 Pervasive developmental disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023409-37 Sponsor Protocol Number: AMLSG_15-10 Start Date*: 2011-03-02
    Sponsor Name:University Hospital Ulm
    Full Title: Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM...
    Medical condition: Adult patients (>60) with AML and NPM1 mutation ineligible for intensive chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005694-23 Sponsor Protocol Number: CB-17-01/05 Start Date*: 2011-12-20
    Sponsor Name:COSMO TECHNOLOGIES LTD
    Full Title: Polyp detection rate after single oral dose of methylene blue MMX(R) modified release tablets administered to subjects undergoing outpatients colonoscopy
    Medical condition: patients scheduled for the screening or surveillance colonoscopy and meeting the joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer and the Ameri...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10014805 Endoscopy PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048832 Colon adenoma PT
    14.1 10017947 - Gastrointestinal disorders 10048646 Polyp colorectal PT
    Population Age: Newborns, Infants and toddlers, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000929-22 Sponsor Protocol Number: CRI109244 Start Date*: 2007-07-06
    Sponsor Name:GlaxoSmithKline R & D Limited
    Full Title: A double-blind, randomised, placebo controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF-1 antagonists GSK561679 and GW876008 on meal induced cortisol respo...
    Medical condition: Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023003 Irritable bowel syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000649-11 Sponsor Protocol Number: SSAT046 Start Date*: 2012-08-22
    Sponsor Name:St Stephen's Aids Trust
    Full Title: A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study...
    Medical condition: HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-001967-70 Sponsor Protocol Number: AC-052-367 Start Date*: 2005-10-13
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: An open-label, long-term, safety, and tolerability extension study using the pediatric formulation of bosentan in the treatment of children with idiopathic or familial pulmonary arterial hypertensi...
    Medical condition: Idiopathic or familial pulmonary arterial hypertension
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 35  36  37  38  39  40  41  42  43  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 05:23:15 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA